Related Experiment Video

Updated: May 20, 2026

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
08:56

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

Molecular targets for the treatment of fibrosing cholangiopathies

L J Maillette de Buy Wenniger1, R P Oude Elferink, U Beuers

  • 1Department of Gastroenterology and Hepatology, Tytgat Institute for Liver and Intestinal Research, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

Clinical Pharmacology and Therapeutics
|August 2, 2012
PubMed

Insights

Novel treatments for fibrosing cholangiopathies are emerging. While ursodeoxycholic acid (UDCA) offers limited benefits, new drugs targeting hepatobiliary mechanisms may offer disease-modifying therapies for cholangiopathies.

Area of Science:

  • Hepatology and Gastroenterology
  • Fibrosing Cholangiopathies Research

Background:

  • Current treatments for fibrosing cholangiopathies, including ursodeoxycholic acid (UDCA), have limited efficacy in healing the disease.
  • Emerging pathophysiologic insights are paving the way for innovative therapeutic strategies.

Purpose of the Study:

  • To explore novel approaches for treating fibrosing cholangiopathies.
  • To identify potential new classes of disease-modifying anti-cholangiofibrotic drugs.

Main Methods:

  • Review of emerging pathophysiologic insights.
  • Analysis of current treatment limitations.
  • Exploration of potential therapeutic targets.

Main Results:

  • Ursodeoxycholic acid (UDCA) may slow progression but does not heal fibrosing cholangiopathies.
  • Immunosuppressive interventions aim to reduce immune-mediated damage.
  • Modulators of hepatobiliary secretory and cytoprotective mechanisms show promise.

Conclusions:

  • New therapeutic strategies are needed beyond current treatments like UDCA.
  • Targeting specific hepatobiliary mechanisms could lead to effective disease-modifying drugs for fibrosing cholangiopathies.

More Related Videos

A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia09:12

A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia

Published on: February 3, 2023

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis04:38

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis

Published on: March 28, 2018

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...